The miR matrix for KLF9 in lung cancers is particularly striking and large, and thus is a potential drug target in this malignancy, providing KLF9 is indeed confirmed to be beneficial to lung cancer patient prognosis. The gene discussed is KLF9; the disease is lung cancer.